However, in a prostate cancer progression cohort consisting of 219 samples from patients with primary prostate cancer, lymph nodes and distant metastases, EVI1 was found to be heterogeneously distributed within samples [26]. This evidence concerns the gene MECOM and prostate carcinoma.